Table 3 PAH-targeted therapy before and after RHC in WHO group 1 PH, WHO group 2 PH, and hyperdynamic PH
|  | WHO group 1 PH n = 138 | WHO group 2 PH n = 33 | Hyperdynamic PH n = 31 | p value |
|---|---|---|---|---|
PAH-targeted therapy before RHC, No. (%) | 70 (50.7) | 22 (66.7) | 20 (64.5) | 0.151 |
PAH-targeted therapy after RHC, No. (%) | 103 (83.3) | 20 (60.6) | 11 (35.5) |  < 0.01 |
 Monotherapy, No. (%) | 89 (64.5) | 13 (39.4) | 8 (25.8) |  |
 Combined therapy, No. (%) | 25 (18.1) | 7 (21.2) | 3 (9.7) |  |
 ERA, No. (%) | 60 (43.8) | 12 (37.5) | 7 (22.6) |  |
 PDE-I, No. (%) | 79 (57.7) | 14 (43.8) | 7 (22.6) |  |
 PGs, No. (%) | 3 (2.2) | 0 (0) | 0 (0) |  |
 GCA, No. (%) | 0 (0) | 0 (0) | 1 (3.2) |  |